Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Lung Cancer

  Free Subscription


06.05.2019

1 Ann Oncol
1 Arch Bronconeumol
1 BMC Cancer
2 Cancer Chemother Pharmacol
1 Chest
3 Clin Lung Cancer
1 J Clin Invest
4 J Thorac Oncol
15 Lung Cancer
4 Oncogene
4 Oncologist
1 PLoS One
2 Proc Natl Acad Sci U S A
1 Thorax


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Oncol

  1. ROTA M, Pizzato M, La Vecchia C, Boffetta P, et al
    Efficacy of lung cancer screening appears to increase with prolonged intervention: results from the MILD trial and a meta-analysis.
    Ann Oncol. 2019 May 2. pii: 5482568. doi: 10.1093.
    PubMed     Text format    


    Arch Bronconeumol

  2. MARTINEZ PEREZ E, de Aguiar Quevedo K, Arraras Martinez M, Cruz Mojarrieta J, et al
    Lung Cancer Screening: Use of Low-Dose Computed Tomography.
    Arch Bronconeumol. 2019 Apr 26. pii: S0300-2896(19)30123.
    PubMed     Text format     Abstract available


    BMC Cancer

  3. EICHHORN F, Klotz LV, Bischoff H, Thomas M, et al
    Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.
    BMC Cancer. 2019;19:413.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  4. CHEN J, Liu B, Zhang F, Cui W, et al
    Pharmacokinetics and safety of lobaplatin plus etoposide in Chinese men older than 65 years with extensive-stage small cell lung cancer: a phase II clinical trial.
    Cancer Chemother Pharmacol. 2019 Apr 30. pii: 10.1007/s00280-019-03828.
    PubMed     Text format     Abstract available

  5. LI Z, Wang M, Yu D, Luo W, et al
    Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2019 Apr 29. pii: 10.1007/s00280-019-03848.
    PubMed     Text format     Abstract available


    Chest

  6. KINOSHITA T, Effat A, Gregor A, Inage T, et al
    A novel laser fiberscope for simultaneous imaging and phototherapy of peripheral lung cancer.
    Chest. 2019 Apr 26. pii: S0012-3692(19)30875-X. doi: 10.1016/j.chest.2019.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  7. LUTFI W, Schuchert MJ, Dhupar R, Ekeke C, et al
    Node-Positive Segmentectomy for Non-Small-Cell Lung Cancer: Risk Factors and Outcomes.
    Clin Lung Cancer. 2019 Apr 1. pii: S1525-7304(19)30079.
    PubMed     Text format     Abstract available

  8. VOONG KR, Hazell SZ, Fu W, Hu C, et al
    Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2019 Mar 28. pii: S1525-7304(19)30068.
    PubMed     Text format     Abstract available

  9. YU T, Shin IS, Yoon WS, Rim CH, et al
    Stereotactic Body Radiotherapy for Centrally Located Primary Non-Small-Cell Lung Cancer: A Meta-Analysis.
    Clin Lung Cancer. 2019 Mar 19. pii: S1525-7304(19)30073.
    PubMed     Text format     Abstract available


    J Clin Invest

  10. KELLISH P, Shabashvili D, Rahman MM, Nawab A, et al
    Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival.
    J Clin Invest. 2019;130.
    PubMed     Text format     Abstract available


    J Thorac Oncol

  11. REMON J, Reguart N, Auclin E, Besse B, et al
    Immune-Related Adverse Events and Outcomes in Patients with Advanced Non-Small Cell Lung Cancer: A Predictive Marker of Efficacy?
    J Thorac Oncol. 2019 Apr 23. pii: S1556-0864(19)30202.
    PubMed     Text format    

  12. MEHLMAN C, Chaabane N, Lacave R, Kerrou K, et al
    Ceritinib ALK T1151R Resistance Mutation in Lung Cancer With Initial Response to Brigatinib.
    J Thorac Oncol. 2019;14:e95-e96.
    PubMed     Text format    

  13. ZHANG J, Wang J, Qian Z, Han Y, et al
    CCR5 is Associated With Immune Cell Infiltration and Prognosis of Lung Cancer.
    J Thorac Oncol. 2019;14:e102-e103.
    PubMed     Text format    

  14. AHN MJ
    Combination of Osimertinib with Durvalumab in Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: Is There Room for Reinvestigation?
    J Thorac Oncol. 2019;14:766-767.
    PubMed     Text format    


    Lung Cancer

  15. YAN SX, Qureshi MM, Dyer M, Truong MT, et al
    Stereotactic body radiation therapy with higher biologically effective dose is associated with improved survival in stage II non-small cell lung cancer.
    Lung Cancer. 2019;131:147-153.
    PubMed     Text format     Abstract available

  16. CHRISTENSEN NL, Dalton S, Ravn J, Christensen J, et al
    Treatment, no treatment and early death in Danish stage I lung cancer patients.
    Lung Cancer. 2019;131:1-5.
    PubMed     Text format     Abstract available

  17. YAMADA T, Ohta K, Motooka Y, Fujino K, et al
    Significance of Tsukushi in lung cancer.
    Lung Cancer. 2019;131:104-111.
    PubMed     Text format     Abstract available

  18. LATTUCA-TRUC M, Timsit JF, Levra MG, Ruckly S, et al
    Trends in response rate and survival in small-cell lung cancer patients between 1997 and 2017.
    Lung Cancer. 2019;131:122-127.
    PubMed     Text format     Abstract available

  19. YIN K, Li YS, Zheng MM, Jiang BY, et al
    A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases.
    Lung Cancer. 2019;131:134-138.
    PubMed     Text format     Abstract available

  20. FOSTER CC, Rusthoven CG, Sher DJ, Feldman L, et al
    Corrigendum to "Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall survival: A National Cancer Database Analysis" [Lung Cancer, Volume 130 (April) (2019) 162-168].
    Lung Cancer. 2019 Apr 25. pii: S0169-5002(19)30398.
    PubMed     Text format    

  21. HARRIS EJA, Musk AW, DeKlerk N, Brims FJH, et al
    Correspondence regarding "Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos".
    Lung Cancer. 2019 Apr 20. pii: S0169-5002(19)30417.
    PubMed     Text format    

  22. NISHIO M, Nakagawa K, Mitsudomi T, Yamamoto N, et al
    Corrigendum to "Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer" [Lung Cancer 121 (July) (2018) Pages 37-40].
    Lung Cancer. 2019 Apr 24. pii: S0169-5002(19)30399.
    PubMed     Text format    

  23. TAKANO N, Ariyasu R, Koyama J, Sonoda T, et al
    Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995-2017.
    Lung Cancer. 2019;131:69-77.
    PubMed     Text format     Abstract available

  24. LIN C, Shi X, Yang S, Zhao J, et al
    Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
    Lung Cancer. 2019;131:62-68.
    PubMed     Text format     Abstract available

  25. PEROL M, Winfree KB, Cuyun Carter G, Lin Cui Z, et al
    Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancer.
    Lung Cancer. 2019;131:6-13.
    PubMed     Text format     Abstract available

  26. SULLIVAN DR, Eden KB, Dieckmann NF, Golden SE, et al
    Understanding patients' values and preferences regarding early stage lung cancer treatment decision making.
    Lung Cancer. 2019;131:47-57.
    PubMed     Text format     Abstract available

  27. WILLEN L, Berglund A, Bergstrom S, Bergqvist M, et al
    Educational level and management and outcomes in non-small cell lung cancer. A nationwide population-based study.
    Lung Cancer. 2019;131:40-46.
    PubMed     Text format     Abstract available

  28. VAYR F, Savall F, Bigay-Game L, Soulat JM, et al
    Lung cancer survivors and employment: A systematic review.
    Lung Cancer. 2019;131:31-39.
    PubMed     Text format     Abstract available

  29. MAISONNEUVE P, Rampinelli C, Bertolotti R, Misotti A, et al
    Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos.
    Lung Cancer. 2019;131:23-30.
    PubMed     Text format     Abstract available


    Oncogene

  30. GE X, Li GY, Jiang L, Jia L, et al
    Long noncoding RNA CAR10 promotes lung adenocarcinoma metastasis via miR-203/30/SNAI axis.
    Oncogene. 2019;38:3061-3076.
    PubMed     Text format     Abstract available

  31. FEDOROVA O, Petukhov A, Daks A, Shuvalov O, et al
    Orphan receptor NR4A3 is a novel target of p53 that contributes to apoptosis.
    Oncogene. 2019;38:2108-2122.
    PubMed     Text format     Abstract available

  32. NISHIMURA T, Nakata A, Chen X, Nishi K, et al
    Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2.
    Oncogene. 2019;38:2464-2481.
    PubMed     Text format     Abstract available

  33. ABDELWAHAB EMM, Pal S, Kvell K, Sarosi V, et al
    Mitochondrial dysfunction is a key determinant of the rare disease lymphangioleiomyomatosis and provides a novel therapeutic target.
    Oncogene. 2019;38:3093-3101.
    PubMed     Text format     Abstract available


    Oncologist

  34. RYU JS, Lim JH, Lee MK, Lee SJ, et al
    Feasibility of Bronchial Washing Fluid-Based Approach to Early-Stage Lung Cancer Diagnosis.
    Oncologist. 2019 Apr 29. pii: theoncologist.2019-0147.
    PubMed     Text format     Abstract available

  35. DUMA N, Abdel-Ghani A, Yadav S, Hoversten KP, et al
    Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?
    Oncologist. 2019 Apr 29. pii: theoncologist.2019-0094.
    PubMed     Text format     Abstract available

  36. CHIHARA Y, Yoshimura A, Date K, Takemura Y, et al
    Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer.
    Oncologist. 2019 Apr 30. pii: theoncologist.2019-0290.
    PubMed     Text format     Abstract available

  37. ZHENG L, Wang Y, Xu Z, Yang Q, et al
    Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations.
    Oncologist. 2019 Apr 30. pii: theoncologist.2019-0285.
    PubMed     Text format     Abstract available


    PLoS One

  38. YUN PJ, Wang GC, Chen YY, Wu TH, et al
    Brain metastases in resected non-small cell lung cancer: The impact of different tyrosine kinase inhibitors.
    PLoS One. 2019;14:e0215923.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  39. IKEMURA S, Yasuda H, Matsumoto S, Kamada M, et al
    Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations.
    Proc Natl Acad Sci U S A. 2019 May 1. pii: 1819430116.
    PubMed     Text format     Abstract available

  40. YAN Z, Huang N, Wu W, Chen W, et al
    Genome-wide colocalization of RNA-DNA interactions and fusion RNA pairs.
    Proc Natl Acad Sci U S A. 2019;116:3328-3337.
    PubMed     Text format     Abstract available


    Thorax

  41. EDBROOKE L, Aranda S, Granger CL, McDonald CF, et al
    Multidisciplinary home-based rehabilitation in inoperable lung cancer: a randomised controlled trial.
    Thorax. 2019 May 2. pii: thoraxjnl-2018-212996.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: